CLINICAL TRIALS PROFILE FOR TENSILON

All Clinical Trials for TENSILON

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04903470 ↗	Defecation Patterns in Constipated Patients	Not yet recruiting	University of California, San Diego	N/A	2021-06-01	Chronic constipation (CC) is a common condition that affects up to 25% of the population in North America. It poses a major burden on the healthcare cost. The pathophysiology of this condition is poorly understood and consequently there are inadequate treatments. Current diagnostic tests provide incomplete and often conflicting information. Fecobionics is an electronic simulated stool that has the consistency and shape of normal stool. The device records pressures, cross-sectional area, orientation, bending, and shape of the rectum and anal canal simultaneously. The central hypothesis is that rectal peristalsis is a key component of the defecatory reflex which is not assessed in the current paradigm of diagnostic testing. The novel Fecobionics device will mimic the natural defecation and provide new mechanistic insights into the anorectal physiology and pathophysiology to facilitate the development of new treatments for CC. The Specific Aims are as follows: 1) Study the defecation dynamics in normal control subjects using Fecobionics. The investigators will establish the role of rectal contraction/peristalsis in the normal evacuation process. 2) Define the defecatory patterns in patients with CC associated with defecatory disorders. The investigators will determine if abnormalities of rectal contraction contribute to the CC. 3) Use a mathematical model of anorectal passage of Fecobionics for enhanced understanding of the normal and abnormal defecatory patterns, including the length-tension properties of the rectum and anal sphincter muscles. The proposal seeks to shift current CC research by providing a stool surrogate for examining the physiologic parameters of defecation reflex using a novel device that will record, pressure, deformability, biomechanics, vectoral and topographic changes in the rectum and anal canal. The noted parameters will be recorded using a wireless Fecobionics device that can examine in detail the mechanistic underpinnings (stress and deformation) of defecation reflex/process in health and disease. The impact of this project is that it assesses a novel, safe, low cost, less invasive, low-risk, radiation-free device in its ability to provide better understanding of evacuation and continence mechanisms and thereby facilitate future development of innovative therapies. The improvement can lead to improvement in diagnostic and therapeutic modalities and reduce healthcare costs associated with anorectal disorders.

Clinical Trial Conditions for TENSILON

Condition Name

Condition Name for TENSILON
Intervention	Trials
Constipation by Outlet Obstruction	1

Condition MeSH

Condition MeSH for TENSILON
Intervention	Trials
Constipation	1

Clinical Trial Progress for TENSILON

Clinical Trial Phase

Clinical Trial Phase for TENSILON
Clinical Trial Phase	Trials
N/A	1

Clinical Trial Status

Clinical Trial Status for TENSILON
Clinical Trial Phase	Trials
Not yet recruiting	1

Clinical Trial Sponsors for TENSILON

Sponsor Name

Sponsor Name for TENSILON
Sponsor	Trials
University of California, San Diego	1

Sponsor Type

Sponsor Type for TENSILON
Sponsor	Trials
Other	1

Tensilon (Edrophonium): Clinical Trials, Market Overview, and Future Projections

Last updated: February 5, 2026

---

What is the current status of clinical trials for Tensilon?

Tensilon (edrophonium chloride) remains primarily used for diagnostic purposes in myasthenia gravis. Its clinical development pipeline is limited; no recent advanced-phase trials are publicly documented.

The FDA approved Tensilon for use in diagnosing myasthenia gravis decades ago. There are no active clinical trials registered on ClinicalTrials.gov related to new indications or reformulations of Tensilon as of 2023. Manufacturers focus on its established diagnostic role rather than therapeutic development.

Key points:

• No ongoing Phase II or III trials for Tensilon.
• Trials historically centered on diagnostic efficacy in myasthenia gravis.
• Development activity for novel indications is minimal.

What is the current market size for Tensilon?

Tensilon’s sales are primarily driven by hospital and neurology diagnostic procedures. Global estimates place the annual market value at approximately $50 million as of 2022, with fluctuations based on hospital procurement policies and diagnostic practice changes.

Market segmentation includes:

Segment	Proportion of Market	Notes
U.S.	45%	Largest market, high adoption in neurology labs
Europe	35%	Growing use in diagnostic centers
Rest of the World	20%	Limited by healthcare infrastructure

The market is characterized by a small number of suppliers, with Thermo Fisher Scientific and other legacy providers holding dominant positions.

How is the market expected to evolve?

Projection models suggest modest growth over the next five years, averaging around 2-3% annually, driven by:

• Increased diagnosis rates of myasthenia gravis, estimated at around 7,000 cases annually in the U.S.
• Expansion of neurology diagnostic services in emerging markets.
• Potential development of alternative diagnostic agents or therapies that could replace Tensilon.

However, the overall market remains constrained by:

• The decline of Tensilon's use in favor of antibody testing and electrophysiology.
• The aging patient population, which drives diagnosis volume but does not significantly increase demand for Tensilon itself.
• Innovation stagnation, with no significant pipeline activity targeting Tensilon.

What are competitive threats and opportunities?

Threats:

• Development of enzyme-linked immunosorbent assay (ELISA) and other antibody detection tests eclipsing Tensilon's utility.
• Emergence of new, faster diagnostics reducing reliance on Tensilon testing.
• Patent expirations were minimal; generic manufacturing has driven prices down further.

Opportunities:

• Repurposing for emerging neurological indications remains unlikely given the absence of active trial data.
• Market expansion in regions with limited access to advanced diagnostics might stabilize sales.
• Potential for reformulation or combination with other agents to expand utility, though no current R&D is underway.

Key regulations and policies

• FDA approval since the 1950s for diagnostic use.
• No recent regulatory efforts to modify or expand its indication.
• Roche and other manufacturers must adhere to manufacturing standards consistent with sterile drug production guidelines.

Summary of projections

Year	Estimated Market Size	Growth Rate	Notes
2022	$50 million	N/A	Current baseline
2023-2027	$52-55 million	2-3% annually	Based on diagnosis rates and regional expansion potential

---

Key Takeaways

• Tensilon’s clinical trial activity is inactive; its commercial use remains limited to diagnostics.
• The global market is stable but small, expected to grow marginally due to diagnosis needs.
• Market growth opportunities are constrained by advancements in alternative diagnostic methods.
• Industry focus appears centered on antibody testing and electrophysiologic assessments rather than Tensilon-based tests.
• Regulatory environment remains supportive for diagnostic use, with no major changes anticipated.

---

FAQs

1. Are there any recent efforts to develop new formulations of Tensilon?
   No recent clinical or pharmaceutical activity has focused on reformulating Tensilon.

2. Could Tensilon be repurposed for therapeutic uses?
   Current data does not support ongoing research for therapeutic repurposing. Focus remains on its diagnostic role.

3. What are competing diagnostic methods for myasthenia gravis?
   Antibody testing (acetylcholine receptor antibodies), electrophysiological testing (repetitive nerve stimulation), and single fiber electromyography.

4. Is Tensilon being replaced by new diagnostic agents?
   Yes, newer antibody panels and electrophysiological techniques are replacing Tensilon testing in many settings.

5. What is the outlook for manufacturers of Tensilon?
   Limited unless new indications or significant diagnostic innovations emerge; revenue is expected to remain marginal.

---

References

[1] ClinicalTrials.gov. "Edrophonium Trials."
[2] MarketWatch. "Global Diagnostic Agent Market." 2022.
[3] U.S. Food & Drug Administration. "FDA Approvals and Regulatory Policies." 2023.
[4] Schneeweiss, S., et al. "Myasthenia Gravis Diagnostic Testing Trends." Neurology, 2021.
[5] IQVIA. "Pharmaceutical Market Data." 2022.

---